Invited review
Recent developments in the field of antitumour anthracyclines

https://doi.org/10.1016/S0223-5234(01)01244-2Get rights and content

Section snippets

Acknowledgements

I am indebted to Dr. J. Robert for information on the topic and to Dr. J.-P. Buisson for critical reading of the manuscript.

First page preview

First page preview
Click to open first page preview

References (127)

  • D.A. Gewirtz

    Biochem. Pharmacol.

    (1999)
  • L. Debusscher et al.

    Eur. J. Cancer Clin. Oncol.

    (1985)
  • K. Mross et al.

    Eur. J. Cancer

    (1990)
  • P.F. Wiley et al.

    Tetrahedron Lett.

    (1968)
  • W. Priebe et al.

    Pharmacol. Ther.

    (1993)
  • F. Arcamone

    Biochimie

    (1998)
  • F. Arcamone et al.

    Pharmacol. Ther.

    (1997)
  • J.F. Money-Kyrle et al.

    Clin. Oncol.

    (1993)
  • A.A. Garcia et al.

    Ann. Oncol.

    (1998)
  • D.E. Lopes de Menezes et al.

    Biochim. Biophys. Acta

    (2000)
  • K. Breistol et al.

    Eur. J. Cancer

    (1998)
  • K. Breistol et al.

    Eur. J. Cancer

    (1999)
  • G.M. Dubowchik et al.

    Bioorg. Med. Chem. Lett.

    (1998)
  • G.M. Dubowchik et al.

    Bioorg. Med. Chem. Lett.

    (1998)
  • H. Nogusa et al.

    Bioorg. Med. Chem. Lett.

    (2000)
  • R. Duncan et al.

    J. Controlled Release

    (1992)
  • I. Niculescu-Duvaz et al.

    Adv. Drug Deliv. Rev.

    (1997)
  • F. Arcamone

    Doxorubicin, Anticancer Antibiotics

    (1981)
  • K.M. Tewey et al.

    Science

    (1984)
  • A.U. Buzdar et al.

    Cancer

    (1985)
  • V.J. Ferrans

    Cancer Treat. Rep.

    (1978)
  • F. Arcamone et al.

    Biotechnol. Bioeng.

    (1969)
  • Suarato, A., Angelucci, F., Bargiotti, A., Chimicoggi (1990)...
  • F. Arcamone et al.

    Curr. Med. Chem.

    (1998)
  • A. Suarato et al.

    Curr. Pharm. Des.

    (1999)
  • T. Oki et al.

    J. Antibiot.

    (1977)
  • T. Oki et al.

    J. Antibiot.

    (1975)
  • R. Maral et al.

    C. R. Acad. Sci. Ser. D

    (1972)
  • F. Arcamone et al.

    Cancer Treat. Rep.

    (1976)
  • A.J. Coukell et al.

    Drugs

    (1997)
  • W. Kreis et al.

    Cancer Res.

    (1988)
  • H. Umezawa et al.

    J. Antibiot.

    (1979)
  • J. Robert
  • M. Israel et al.

    Cancer Res.

    (1975)
  • P.F. Wiley et al.

    J. Org. Chem.

    (1979)
  • T. Taguchi et al.

    Gan To Kagaku Ryoho

    (1997)
  • T. Taguchi et al.

    Gan To Kagaku Ryoho

    (1997)
  • G.R. Weiss et al.

    Invest. New Drugs

    (1993)
  • C. Mazurek et al.

    Invest. New Drugs

    (1993)
  • D.J. Stewart et al.

    J. Neurooncol.

    (1992)
  • S.P. Sim et al.

    Biochemistry

    (1997)
  • N. Komeshima et al.

    J. Antibiot.

    (1988)
  • C. Sessa et al.

    Cancer Chemother. Pharmacol.

    (1999)
  • M. Ripamonti et al.

    Invest. New Drugs

    (1996)
  • S. Marchini et al.

    Anticancer Drug Des.

    (1995)
  • C. Geroni et al.

    Cancer Res.

    (2001)
  • S. Marchini et al.

    Cancer Res.

    (2001)
  • Suarato, A., Caruso, M., Geroni, C., Capolongo, L., Pennella, G., 217th ACS National Meeting, Anaheim, CA, 21–25 March...
  • C.A. Pawlik et al.

    Oncol. Res.

    (1998)
  • D. Booser et al.

    Proc. Am. Soc. Clin. Oncol.

    (1997)
  • Cited by (148)

    • Green preparation of carbon dots from plum as a ratiometric fluorescent probe for detection of doxorubicin

      2021, Optical Materials
      Citation Excerpt :

      It can kill cancer cells by inhibiting the synthesis of RNA and DNA in the cancer cell cycle [1,2]. On the other hand, DOX has some side-effects of causing bone marrow suppression and cardiotoxicity [3]. In clinic, monitoring the concentration of DOX in human biofluids can guide its reasonable clinical dosage, thereby ensuring the effectiveness of treatment and minimizing the toxicity to patients.

    View all citing articles on Scopus
    View full text